News related to
shares

The airlines signed a memorandum of understanding that establishes a framework for negotiating a future joint business agreement. The proposed arrangement would deepen their existing codeshare relationship and could allow closer coordination across schedules, sales, network planning and passenger services.

The partnership is expected to explore single-ticket journeys across the two carriers’ combined networks. Garuda Indonesia passengers could gain easier access to Saudia-operated destinations in the Middle East, Europe and Africa, while Saudia customers could connect through Garuda’s domestic network and services to Australia.

The carriers will examine coordinating flight schedules between Saudi Arabia and Indonesia to improve connection times and reduce lengthy transfers. They will also assess joint sales, marketing and distribution initiatives in markets where both airlines see opportunities for traffic growth.

Cooperation could extend to frequent-flyer programmes, airport services, technology systems and customer handling. The memorandum also places particular emphasis on services for Umrah and Hajj passengers travelling from Indonesia, one of the world’s largest markets for pilgrimage-related air travel.

Saudia Chief Commercial Officer Arved von zur Muehlen and Garuda Indonesia Director of Transformation Neil Raymond Mills signed the agreement. The ceremony was attended by Saudia Group Director General Ibrahim Al-Omar and Garuda Indonesia Vice President Director Thomas Sugiarto Oentoro.

Von zur Muehlen said the agreement reflected Saudia’s strategy of building commercial partnerships that strengthen its international network. He said the proposed cooperation would offer passengers greater flexibility between Indonesia, Australia and destinations served by Saudia across three regions.

Mills said the partnership carried strategic value beyond expanding flight networks. Improved access to the Middle East, Europe and Africa would support pilgrimage travel, family and community movement, business links and wider economic cooperation.

A joint business agreement would represent a deeper form of cooperation than a conventional codeshare. Codeshares allow airlines to sell seats on flights operated by a partner, while joint business structures can involve coordinated scheduling, pricing, sales and capacity planning, subject to regulatory approval.

Such arrangements allow airlines to extend their market reach without immediately adding aircraft or launching a large number of new routes. They can also improve aircraft utilisation and feed passenger traffic through major hubs. Regulators, however, generally examine these partnerships to ensure that closer coordination does not weaken competition or limit consumer choice.

The proposed partnership builds on the airlines’ membership of the SkyTeam alliance. Saudia joined SkyTeam in 2012, while Garuda Indonesia became a member in 2014. Alliance membership already supports shared passenger benefits, lounge access, priority services and frequent-flyer recognition across participating carriers.

Saudia operates from hubs including Jeddah, Riyadh, Dammam and Medina, connecting Saudi Arabia with destinations across Asia, Africa, Europe and North America. Its Jeddah hub is particularly important for religious travel because of its proximity to Makkah and its role as a gateway for pilgrims.

Garuda Indonesia’s network is centred on Jakarta and Bali, with domestic services covering major commercial centres and tourism destinations across the archipelago. Its international operations connect Indonesia with markets in Asia, the Middle East and Australia.

The agreement comes as Garuda expands commercial cooperation with overseas airlines during its continuing operational and financial restructuring. The carrier launched a codeshare partnership with Scandinavian Airlines in June, offering connections between Indonesia and Copenhagen, Stockholm and Oslo through hubs including Amsterdam and Tokyo.

Greater cooperation with Saudia could strengthen Garuda’s access to markets that are difficult to serve economically with direct flights. The arrangement could also help generate connecting traffic for domestic destinations beyond Jakarta, including cities that supply significant numbers of Umrah and Hajj travellers.

Indonesia and Saudi Arabia have sought to expand economic and transport ties alongside their strong religious and cultural links. Agreements between companies from the two countries valued at about $27 billion were announced in 2025 across sectors including clean energy, petrochemicals and aviation fuel services.

Trump announced that generic drugs entering the United States would remain free of import duties until August 1, 2028. A tariff of 100% would then apply for one year, followed by a 200% levy from August 2029. The proposed schedule extends Washington’s pharmaceutical reshoring campaign beyond patented and branded medicines, which were targeted earlier.

India faces the greatest exposure because the United States is its largest pharmaceutical export market. Drug exports to the country were valued at about $9.7 billion in 2025, representing roughly 38% of total pharmaceutical shipments worth $25.8 billion.

The policy nevertheless does not automatically remove the price advantage enjoyed by manufacturers such as Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Aurobindo Pharma, Cipla, Lupin and Zydus Lifesciences. Many generic medicines produced in India are priced seven to 10 times below branded alternatives, leaving room for some products to remain competitive even after steep duties.

A medicine imported for $10 would cost $30 after a 200% tariff, excluding distribution and retail charges. It could still undercut a branded equivalent priced at $70 or $100. The calculation is less favourable for commodity generics, where several manufacturers compete on narrow margins and buyers demand the lowest possible price.

Generic medicines account for more than 90% of prescriptions dispensed in the United States but less than 13% of prescription-drug spending. That imbalance reflects their importance to American healthcare as well as the pressure placed on manufacturers by pharmacy chains, wholesalers, insurers and purchasing organisations.

The United States imported pharmaceutical products valued at about $213 billion in 2025. Finished medicines sold in retail packaging, including generic products, accounted for about $94.1 billion. Replacing those imports would require extensive investment, specialised workers, regulatory approvals and dependable supplies of active pharmaceutical ingredients.

Building a pharmaceutical plant can take several years. Companies must install production lines, validate manufacturing processes and secure approval from the US Food and Drug Administration before commercial sales begin. Each medicine may also require separate technical submissions and inspections, complicating attempts to shift large portfolios within the two-year exemption period.

Several major drugmakers have already established manufacturing or research operations in the United States, providing limited protection against future tariffs. Companies may expand those facilities, acquire local plants or transfer selected high-volume products while continuing to manufacture lower-margin medicines overseas.

The tariff could affect businesses unevenly. Manufacturers with specialised generics, injectable drugs, inhalers and complex formulations may have greater pricing power. Producers dependent on crowded categories such as basic tablets and capsules could face heavier pressure because customers can switch suppliers more easily.

Shares of leading pharmaceutical companies fell after the announcement, with some declining by more than 3% during Wednesday’s trading. The reaction reflected concern over long-term earnings rather than an immediate change in export conditions, as the duty-free window remains open for two years.

Implementation is also uncertain. Trump disclosed the schedule through a social-media statement, but no detailed executive order or customs framework had been issued. The administration must still clarify whether exemptions will be available for companies building factories, medicines facing shortages, critical hospital products or imports from countries covered by trade agreements.

Industry participants are expected to seek exclusions for essential medicines, arguing that tariffs could raise treatment costs and deepen shortages. The American generic-drug market has already faced supply disruptions linked to plant closures, quality failures and unsustainable pricing. Higher import costs could encourage some manufacturers to withdraw products rather than invest in additional capacity.

Washington’s strategy also faces a supply-chain constraint beyond finished medicines. A large portion of the active ingredients and chemical intermediates used by global manufacturers originates in China. Moving final production to the United States without diversifying those inputs would provide only partial protection against overseas disruption.

Drugmakers in India now have until August 2028 to adjust their production networks, negotiate with customers and identify medicines capable of absorbing higher duties. Expansion into Europe, Africa, Latin America and other regulated markets could reduce dependence on the United States, although none offers comparable scale.

• Supporting Asia‑Pacific’s transition from BS 476 to the more comprehensive EN 13501‑1 fire‑classification framework
• ArmaPrene™‑based insulation, including ArmaFlex® Ultima, achieves significantly lower smoke emissions to support safer evacuation and fire‑engineering compliance
• ArmaLive Experience Centre builds industry capability through product insights, demonstrations, audits and hands‑on installation training
• Active collaborations with industry partners and relevant public-sector bodies to help shape safer built environments
• Long‑term commitment to safer, more energy‑efficient buildings through technical guidance, training and regional knowledge‑sharing

SINGAPORE – Media OutReach Newswire – 14 July 2026 – Armacell, a global leader in flexible equipment insulation and engineered foams, deepens its collaboration with industry stakeholders across Asia‑Pacific to enhance energy efficiency, sustainability and fire‑safety standards in the built environment.

Central to this expanded engagement is the ArmaLive Experience Centre, which serves as a regional hub for training, technical insight and hands-on demonstrations. The centre is designed to support engineers, consultants, installers and regulatory professionals as they respond to increasingly performance‑based compliance requirements—particularly in the areas of sustainability, energy efficiency and fire safety.

Supporting Asia‑Pacific’s transition to modern fire‑safety standards

Across Asia-Pacific, regulators and industry professionals are steadily moving from legacy BS 476 classifications to the more comprehensive EN 13501‑1 fire-performance framework. This shift reflects a growing focus on smoke‑performance—an essential advancement, as smoke inhalation remains one of the leading causes of fatalities in building fires.

To support this transition, Armacell provides data‑driven guidance, technical resources and targeted training that help stakeholders interpret performance criteria, understand material behaviour and assess system-level implications under the newer standard. These efforts are designed to enable informed specification decisions and support safer fire-engineering outcomes across a wide range of building applications.

A prime example of Armacell’s material innovation is ArmaFlex Ultima, developed using the company’s patented ArmaPrene technology. Generating about ten times less smoke than conventional elastomeric insulation, ArmaFlex Ultima achieves Euroclass B‑s1,d0 performance, enabling specifiers and fire engineers to significantly enhance safety in critical areas such as escape routes, mechanical services and other high-risk building zones.

ArmaLive Experience Centre: Strengthening regional technical capability

Located in Singapore, the ArmaLive Experience Centre delivers an expanded programme of learning and engagement designed to strengthen technical capability across the Asia-Pacific region and raise material and installation standards. The Centre offers a range of practical and knowledge-based initiatives, including:

• Product insight sessions showcasing compliance performance, system reliability and application-specific considerations.
• Energy and acoustic audits to support sustainable mechanical design and operational optimisation.
• Hands‑on installation training to help installers improve workmanship quality, reduce system losses and meet fire-safety and performance requirements.
• Live demonstrations and scenario‑based workshops focused on insulation selection, fire‑performance criteria and correct installation techniques.

Together, these programmes foster closer collaboration among developers, engineers, consultants, contractors and regulators, deepening their understanding of how insulation solutions contribute to energy efficiency, acoustic performance and fire safety.

Driving industry standards through technical partnerships

Armacell works closely with professional associations, technical bodies and relevant public-sector organisations across Asia‑Pacific to help advance technical standards and support a safer, more sustainable built environment.

Through seminars, joint technical exchanges and shared learning initiatives, the company shares expertise in insulation selection, performance benchmarks and comparative material behaviour—strengthening compliance awareness and improving the quality of building design and system specification.

By combining advanced materials knowledge with sustained industry engagement, particularly through the ArmaLive Experience Centre, Armacell supports informed specification practices, builds regional capability and reinforces its long‑term commitment to safer, sustainable and more resilient buildings across Asia-Pacific.
Hashtag: #Armacell

The issuer is solely responsible for the content of this announcement.

About Armacell

As the inventor of flexible foam for equipment insulation and a leading provider of engineered foams, Armacell develops innovative and safe thermal and mechanical insulation solutions that create sustainable value for its customers. Armacell’s products significantly contribute to driving energy efficiency worldwide.

With more than 3,100 employees and 26 production plants in 20 countries, Armacell operates two main businesses, Advanced Insulation and Engineered Foams. Armacell focuses on insulation materials for technical equipment, high-performance foams for acoustic and lightweight applications, recycled PET products, next-generation aerogel technology and passive fire protection systems.

For more information, please visit: www.armacell.com

The online fashion retailer is considering an offer of between $2 billion and $3 billion, although the final size will depend on its valuation, investor demand and prevailing market conditions. The timetable could also change as the company completes the remaining stages of Hong Kong’s listing process.

Shein is scheduled to face the Hong Kong Stock Exchange’s listing committee this week. Approval at the hearing would allow the company and its advisers to move towards investor presentations, price discovery and bookbuilding.

Some people involved in the process expect the shares to begin trading in September or October rather than August, reflecting the time required to complete regulatory documentation and market the offer to institutional investors. A successful listing would rank among Hong Kong’s largest consumer-sector flotations in years.

China’s securities regulator has approved the proposed sale of up to 341.6 million H shares. The clearance removed one of the biggest obstacles confronting Shein, which submitted confidential listing documents in Hong Kong about a year ago after encountering difficulties in New York and London.

The company could seek a valuation of between $40 billion and $50 billion. That would represent a sharp retreat from the $100 billion valuation achieved during a private funding round in 2022, when pandemic-era online shopping growth and investor enthusiasm for digital retail pushed its value above several established fashion groups.

Shein was valued at about $66 billion in 2023. The lower range being discussed for the Hong Kong offer reflects tighter investor scrutiny, greater competition, changing customs rules and concern over the durability of its low-cost cross-border business model.

The retailer, founded in Nanjing in 2012 by entrepreneur Sky Xu and now headquartered in Singapore, sells inexpensive clothing and lifestyle products across roughly 150 markets. Its data-driven system tests products in small batches, measures consumer demand and orders additional stock when items gain traction.

That model has helped Shein respond rapidly to fashion trends while limiting unsold inventory. It has also placed pressure on traditional retailers and brought intense scrutiny of production volumes, environmental impact, working conditions and supplier oversight.

Although Shein has positioned itself as a global company, much of its manufacturing network remains concentrated in China, particularly around Guangzhou and other parts of Guangdong province. That dependence brought the company within the scope of China’s overseas-listing review system despite the relocation of its corporate headquarters.

Shein previously pursued a New York flotation but faced political resistance and demands for deeper examination of its supply chain, data practices and alleged exposure to forced labour in Xinjiang. The company has said it maintains a zero-tolerance policy towards forced labour and requires suppliers to comply with its sourcing standards.

A subsequent attempt to list in London also stalled. Britain’s financial regulator had cleared the company’s prospectus, but the transaction could not proceed without approval from Beijing. Disagreements surrounding disclosures about supply-chain risks complicated the process.

Hong Kong offers Shein a venue closer to its manufacturing base and within a regulatory framework more acceptable to Beijing. The city’s market, however, may produce a lower valuation than the company once expected from New York or London, where international consumer and technology companies have traditionally attracted broader investor coverage.

The proposed offer comes during a strong period for Hong Kong listings. Companies raised about HK$209.9 billion across 85 new flotations during the first half of 2026, the market’s best first-half performance in five years. A pipeline of hundreds of applicants has strengthened expectations that the city could remain among the world’s leading fundraising centres this year.

Shein’s leadership is also changing as the listing approaches. Executive chairman Donald Tang is expected to step down and continue as a senior adviser. Tang played a central role in the company’s engagement with governments, regulators and investors during its attempts to secure a Western listing.

Xu is expected to take a leading role in presenting the investment case to prospective shareholders. Investors are likely to examine Shein’s growth prospects, profit margins and ability to adapt to customs changes, particularly the removal of duty-free treatment for low-value packages entering the United States from China and Hong Kong.